3.8

CiteScore

2.4

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Cheng Wang, Zhengfeng Xu, Guangfu Jin, Zhibin Hu, Juncheng Dai, Hongxia Ma, Yue Jiang, Lingmin Hu, Minjie Chu, Songyu Cao, Hongbing Shen. Genome-wide analysis of runs of homozygosity identifies new susceptibility regions of lung cancer in Han Chinese[J]. The Journal of Biomedical Research, 2013, 27(3): 208-214. DOI: 10.7555/JBR.27.20130017
Citation: Cheng Wang, Zhengfeng Xu, Guangfu Jin, Zhibin Hu, Juncheng Dai, Hongxia Ma, Yue Jiang, Lingmin Hu, Minjie Chu, Songyu Cao, Hongbing Shen. Genome-wide analysis of runs of homozygosity identifies new susceptibility regions of lung cancer in Han Chinese[J]. The Journal of Biomedical Research, 2013, 27(3): 208-214. DOI: 10.7555/JBR.27.20130017

Genome-wide analysis of runs of homozygosity identifies new susceptibility regions of lung cancer in Han Chinese

Funds: 

This work was supported in part the by National Natural Science Foundation of China (81230067, 81270044 and 30901233)

Doctoral Fund of Ministry of Education of China (20093234110001), New Century Excellent Talents in University (NCET-10-0178), and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

More Information
  • Received Date: January 12, 1931
  • Runs of homozygosity (ROHs) are a class of important but poorly studied genomic variations and may be in-volved in individual susceptibility to diseases. To better understand ROH and its relationship with lung cancer, we performed a genome-wide ROH analysis of a subset of a previous genome-wide case-control study (1,473 cases and 1,962 controls) in a Han Chinese population. ROHs were classified into two classes, based on lengths, intermedi-ate and long ROHs, to evaluate their association with lung cancer risk using existing genome-wide single nucleotide polymorphism (SNP) data. We found that the overall level of intermediate ROHs was significantly associated with a decreased risk of lung cancer (odds ratio = 0.63; 95% confidence interval: 0.51-0.77; P = 4.78×10-6 ), while the long ROHs seemed to be a risk factor of lung cancer. We also identified one ROH region at 14q23.1 that was con-sistently associated with lung cancer risk in the study. These results indicated that ROHs may be a new class of variation which may be associated with lung cancer risk, and genetic variants at 14q23.1 may be involved in the development of lung cancer.
  • Related Articles

    [1]Qian Gu, Qin Wang, Rui Hua, Wenhao Zhang, Jianzhen Teng, Jiazheng Ma, Zhou Dong, Xiaoxuan Gong, Chunjian Li. Low RBC counts predict high on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention and treated with clopidogrel[J]. The Journal of Biomedical Research, 2024, 38(1): 87-91. DOI: 10.7555/JBR.37.20230035
    [2]Yao Daokuo, Gao Xiangyu, Zhao Huiqiang, Chen Hui, Wang Lexin. Multivessel coronary artery ectasia and severe calcification in a patient with pheochromocytoma: a case report[J]. The Journal of Biomedical Research, 2019, 33(1): 69-72. DOI: 10.7555/JBR.32.20170047
    [3]Mingming Gao, Guo Xin, Xu Qiu, Yuhui Wang, George Liu. Establishment of a rat model with diet-induced coronary atherosclerosis[J]. The Journal of Biomedical Research, 2017, 31(1): 47-55. DOI: 10.7555/JBR.31.20160020
    [4]Jiawei Liao, Wei Huang, George Liu. Animal models of coronary heart disease[J]. The Journal of Biomedical Research, 2017, 31(1): 3-10. DOI: 10.7555/JBR.30.20150051
    [5]Rajiv Shrestha, Jing Xu, Dujiang Xie, Zhizhong Liu, Tian Xu, Fei Ye, Shiqing Din, Xuesong Qian, Song Yang, Yueqiang Liu, Feng Li, Aiping Zhang, Shaoliang Chen. Comparison of clinical outcomes of Chinese men and women after coronary stenting for coronary artery disease: a multi-center retrospective analysis of 4,334 patients[J]. The Journal of Biomedical Research, 2014, 28(5): 368-375. DOI: 10.7555/JBR.28.20120127
    [6]Xuezhong Wang, Xiaoxuan Gong, Tiantian Zhu, Qiu Zhang, Yangyang Zhang, Xiaowei Wang, Zhijian Yang, Chunjian Li. Clopidogrel improves aspirin response after off-pump coronary artery bypass surgery[J]. The Journal of Biomedical Research, 2014, 28(2): 108-113. DOI: 10.7555/JBR.28.20120139
    [7]Min Zhang, Huiwei He, Ze-Mu Wang, Zhihui Xu, Ningtian Zhou, Zhengxian Tao, Bo Chen, Chunjian Li, Tiebing Zhu, Di Yang, Liansheng Wang, Zhijian Yang. Diagnostic and prognostic value of minor elevated cardiac troponin levels for percutaneous coronary intervention-related myocardial injury: a prospective, single-center and double-blind study[J]. The Journal of Biomedical Research, 2014, 28(2): 98-107. DOI: 10.7555/JBR.28.20130124
    [8]Marina Piccinelli, Ernest Garcia. Multimodality image fusion for diagnosing coronary artery disease[J]. The Journal of Biomedical Research, 2013, 27(6): 439-451. DOI: 10.7555/JBR.27.20130138
    [9]Fang Cui, Yusheng Ren, Heng Jin, Bo Cui. Rehabilitation training improves exercise tolerance after percutaneous coronary intervention[J]. The Journal of Biomedical Research, 2012, 26(4): 248-252. DOI: 10.7555/JBR.26.20110119
    [10]Chunjian Li, Zhijian Yang, Kejiang Cao. Retrieval of dislodged coronary stent from left renal artery by gooseneck snare[J]. The Journal of Biomedical Research, 2010, 24(6): 479-482. DOI: 10.1016/S1674-8301(10)60064-4
  • Cited by

    Periodical cited type(15)

    1. Arsh H, Manoj Kumar F, Simran F, et al. Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review. Ann Med Surg (Lond), 2024, 86(2): 899-908. DOI:10.1097/MS9.0000000000001601
    2. Saputri FC, Azmi NU, Puteri MU, et al. High-Fat Diet Enhances Platelet Activation and Is Associated with Proprotein Convertase Subtilisin Kexin 9: An Animal Study. Nutrients, 2023, 15(20): 4463. DOI:10.3390/nu15204463
    3. Ishikawa H, Nagashima R, Kuno Y, et al. Effects of NKT Cells on Metabolic Disorders Caused by High-Fat Diet Using CD1d-Knockout Mice. Diabetes Metab Syndr Obes, 2023, 16: 2855-2864. DOI:10.2147/DMSO.S428190
    4. Chen PW, Tseng SY, Chang HY, et al. Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity. Int J Mol Sci, 2022, 23(17): 9768. DOI:10.3390/ijms23179768
    5. Ayoub C, Azar Y, Maddah D, et al. Low circulating PCSK9 levels in LPL homozygous children with chylomicronemia syndrome in a syrian refugee family in Lebanon. Front Genet, 2022, 13: 961028. DOI:10.3389/fgene.2022.961028
    6. Bouchard J, Malalgoda M, Storsley J, et al. Health Benefits of Cereal Grain- and Pulse-Derived Proteins. Molecules, 2022, 27(12): 3746. DOI:10.3390/molecules27123746
    7. Majeed ML, Ghafil FA, Fatima G, et al. Anti-Atherosclerotic and Anti-Inflammatory Effects of Curcumin on Hypercholesterolemic Male Rabbits. Indian J Clin Biochem, 2021, 36(1): 74-80. DOI:10.1007/s12291-019-00858-5
    8. Fedoryak O, Arama C, Diarra I, et al. Association of the rs562556 PCSK9 Gene Polymorphism with Reduced Mortality in Severe Malaria among Malian Children. Can J Infect Dis Med Microbiol, 2020, 2020: 9340480. DOI:10.1155/2020/9340480
    9. Drouin-Chartier JP, Tremblay AJ, Hogue JC, et al. Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance. J Lipid Res, 2018, 59(8): 1501-1509. DOI:10.1194/jlr.M086264
    10. Chan DC, Watts GF, Somaratne R, et al. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Arterioscler Thromb Vasc Biol, 2018, 38(7): 1644-1655. DOI:10.1161/ATVBAHA.118.310882
    11. Eroğlu Z, Tetik Vardarlı A, Düzgün Z, et al. Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia. Anatol J Cardiol, 2018, 19(5): 334-340. DOI:10.14744/AnatolJCardiol.2018.86648
    12. Hedayat AF, Park KH, Kwon TG, et al. Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model. Transl Res, 2018, 192: 30-45. DOI:10.1016/j.trsl.2017.10.007
    13. Chen IC, Tseng WK, Li YH, et al. Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9. Oncotarget, 2017, 8(64): 108042-108053. DOI:10.18632/oncotarget.22448
    14. Zhang PY. PCSK9 as a therapeutic target for cardiovascular disease. Exp Ther Med, 2017, 13(3): 810-814. DOI:10.3892/etm.2017.4055
    15. Yu Z, Huang T, Zheng Y, et al. PCSK9 variant, long-chain n-3 PUFAs, and risk of nonfatal myocardial infarction in Costa Rican Hispanics. Am J Clin Nutr, 2017, 105(5): 1198-1203. DOI:10.3945/ajcn.116.148106

    Other cited types(0)

Catalog

    Hongbing Shen

    1. On this Site
    2. On Google Scholar
    3. On PubMed

    Article Metrics

    Article views (3853) PDF downloads (1200) Cited by(15)
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return